Literature DB >> 9258660

Genetic lesions associated with blastic transformation of polycythemia vera and essential thrombocythemia.

G Gaidano1, C Pastore, V Santini, J Nomdedeu, B Gamberi, D Capello, F Vischia, L Resegotti, U Mazza, P R Ferrini, F Lo Coco, G Saglio.   

Abstract

Polycythemia vera (PV) and essential thrombocythemia (ET) are chronic myeloproliferative disorders that may progress to acute leukemia in a subset of patients. This study aimed at investigating the genetic lesions associated with the blastic transformation of PV and ET. A panel of PV and ET cases at different stages of disease was analyzed for the presence of genetic alterations of TP53, NRAS, KRAS, and MDM2 by a combination of mutational analysis and Southern blot hybridization. The occurrence of microsatellite instability (MSI) was also tasted in selected cases. Samples of PV and ET analyzed in chronic phase disease were consistently devoid of all genetic lesions tested, suggesting that alterations of TP53, NRAS, KRAS, and MDM2 do not contribute significantly to development of chronic phase PV and ET. Conversely, mutations of TP53 were detected in 7/15 (46.6%) blastic phase cases, including 3/5 PV and 4/10 ET. In blastic phase patients for whom the corresponding chronic phase DNA was also available, it could be documented that the genetic lesion had arisen at the time of blastic transformation. In addition to TP53 mutations, cases of blastic phase PV and ET occasionally harbored mutations of NRAS (one case of blastic phase ET) or displayed MSI (one case of blastic phase PV). These data indicate that inactivation of TP53 is a relatively frequent event associated with the blastic transformation of PV and ET and may be responsible for the tumor progression of these disorders.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9258660

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  3 in total

1.  Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients.

Authors:  Despina Mavrogianni; Nora Viniou; Evi Michali; Evangelos Terpos; John Meletis; George Vaiopoulos; Marina Madzourani; Gerasimos Pangalis; Xenophon Yataganas; Dimitris Loukopoulos
Journal:  Int J Hematol       Date:  2002-05       Impact factor: 2.490

2.  Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.

Authors:  Iris T Chan; Jeffery L Kutok; Ifor R Williams; Sarah Cohen; Lauren Kelly; Hirokazu Shigematsu; Leisa Johnson; Koichi Akashi; David A Tuveson; Tyler Jacks; D Gary Gilliland
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

3.  JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines.

Authors:  Wanke Zhao; Yanhong Du; Wanting Tina Ho; Xueqi Fu; Zhizhuang Joe Zhao
Journal:  Exp Hematol Oncol       Date:  2012-06-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.